^
Association details:
| Biomarker: | SAMHD1 mutation |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Drug: | cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
SAMHD1 mutations in mantle cell lymphoma are recurrent and confer in vitro resistance to nucleoside analogues
Excerpt:
Cell viability screening showed a significant difference in drug response to the nucleoside analogues cytarabine (adjusted p-value = 1E-04) and fludarabine (adjusted p-value = 4E-03), showing higher cell viability after 48 h in SAMHD1 mutated compared to unmutated patient-derived MCL cells....In conclusion, we report that SAMHD1 is recurrently mutated in MCL and confers resistance to nucleoside analogue therapy in vitro.
DOI:
https://doi.org/10.1016/j.leukres.2021.106608
